Xenon’s Azetukalner Shows Record Efficacy in Phase 3 Epilepsy Trial

Xenon Pharmaceuticals reported strong Phase 3 results for azetukalner in focal onset seizures. The drug reduced monthly seizures by 53.2% vs 10.4% on placebo. NDA filing planned for Q3 2026.